Ketalin (ketamine) is applied across therapeutic domains involving significant symptomatic support, and is primarily applied in areas requiring controlled symptomatic support for consciousness and pain.

The medication is commonly used to help manage severe, high-intensity pain; is applied in settings requiring general anesthesia and short-term procedural sedation; and is relevant in conditions involving heightened emotional distress, such as treatment-resistant depression. Quick Fact: Relevant for Acute Discomfort

Symptom Relief in Acute Clinical Scenarios

Ketalin is commonly used to provide supportive relief from acute, high-intensity pain associated with trauma, fractures, or urgent medical procedures. This is relevant in clinical settings where assistance with managing high-intensity discomfort is needed, helping patients cope more steadily with difficult and overwhelming symptomatic manifestations. It is considered relevant in critical situations for symptom management while assisting with the maintenance of functional stability in contexts involving heightened systemic burden.

For patients experiencing these challenging symptomatic phases, the supportive therapeutic benefit is appropriate. “It may provide the supportive assistance relevant for easing discomfort and managing pain during challenging symptomatic phases.” The medication also plays a role in managing symptoms of severe major depression and acute suicidal thoughts that have not responded to conventional medication, offering rapid supportive relief that helps ease the overall symptom burden.

Regulatory References

1. NIH StatPearls overview

Who can and cannot use Ketalin? — Official Regulatory Information

The eligibility profile for Ketalin is strictly defined by government regulatory documents, which establish absolute non-eligibility, conditional use requirements, and population-specific restrictions.

---

Eligibility Scope

Category	Official Regulatory Statement
Populations for whom use is allowed	Adults and Pediatric Patients.
Populations for whom use is contraindicated	Patients with known hypersensitivity or those for whom a significant elevation of blood pressure would constitute a serious hazard (e.g., severe hypertension).
Age-related eligibility rules	Indicated for adults and children; cautious dose selection is advised for geriatric patients. Use is restricted for children le 3 years for prolonged procedures (ge 3 hours).
Condition-specific eligibility rules	Use requires caution in patients with hepatic impairment, preanesthetic elevated cerebrospinal fluid (CSF) pressure, and increased intraocular pressure.
Pregnancy and lactation eligibility status	Use is not recommended; safe use has not been established.

---

Eligibility Classifications (High-Level)

Category	Regulatory Status/Basis
Eligibility severity classification	Contraindicated, Not Recommended, Use with Caution.
Eligibility-context constraints	Cardiovascular risk, Hypersensitivity, Age/Duration of Use, Organ Function.

---

Connection to the Overall Eligibility Profile

Regulatory documents define Ketalin eligibility primarily through a narrow list of absolute contraindications related to cardiovascular risk and allergy, restricting its use in specific patient groups where its hemodynamic effects could be dangerous. For all other populations, eligibility is defined by conditional use, requiring caution or dose consideration based on age (geriatric, prolonged use in children) and the patient's underlying physiological state, such as liver function or intracranial pressure. The medicine is not recommended for pregnant or breastfeeding patients.

Interactions with other medicines and products

This section describes the officially documented interaction patterns of Ketalin (ketamine) as stated in government regulatory documents.

Category	Documentation Summary (Strictly Regulatory)
Interacting Substances	CNS Depressants (e.g., Opioids, Benzodiazepines, Alcohol), Sympathomimetics, Vasopressin, Theophylline, Aminophylline, Barbiturates.
Pharmacokinetic Effects	Hepatic enzyme inducers (e.g., Barbiturates for long-term use) are documented to decrease ketamine plasma concentrations. CYP enzyme inhibitors (e.g., Clarithromycin) and food products (e.g., Grapefruit juice) can increase S-ketamine exposure.
Contraindicated/Restricted	Co-administration with Theophylline or Aminophylline is a documented interaction risk due to the potential for lowering the seizure threshold. Restrictions apply to co-administration with agents that cause a significant elevation of blood pressure.
Chemical Incompatibility	The injection solution is chemically incompatible with Barbiturates and Diazepam; these substances must not be mixed in the same syringe or infusion fluid due to precipitate formation.
Pharmacodynamic Effects	Concomitant use with CNS depressants (including alcohol) may result in additive profound sedation and respiratory depression. Co-administration with Sympathomimetics enhances their effects, leading to combined increases in heart rate and blood pressure.

Regulatory documents define the product's interaction structure based on two primary categories: pharmacodynamic interactions that pose risks of compounded physiological effects (e.g., severe CNS or cardiac stimulation) and pharmacokinetic interactions that alter the drug's overall exposure by affecting metabolic enzyme activity. These patterns necessitate specific regulatory instructions regarding chemical handling restrictions and formally identified combinations to manage documented hazards.

Ketalin is a rapid-acting, noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist that is highly lipophilic, allowing for rapid central nervous system (CNS) distribution. Its primary biological target is the NMDA receptor, where it binds within the cation channel pore, physically obstructing ion flow and preventing glutamate-stimulated sodium ( Na^+) and calcium ( Ca^2+) influx, thus inhibiting excitatory neurotransmission.

---

This acute blockade of NMDA receptors, particularly those containing the GluN2 B subunit, precipitates a transient increase in extracellular glutamate concentrations. This increased glutamate subsequently drives the allosteric activation of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors on nearby neurons. This downstream activation of the AMPA receptor promotes the synthesis and release of brain-derived neurotrophic factor (BDNF) and activates the mammalian target of rapamycin (mTORC1) signaling cascade.

---

The intracellular consequence of these pathways is the rapid promotion of synaptogenesis and the restoration of synaptic connectivity in specific cerebral regions, resulting in an enduring modulation of neural circuits involved in affect and sensorimotor gating. Ketalin also interacts with other targets, including mu-opioid receptors (partial agonism) and HCN1 channels (blockade), contributing to its systemic physiological consequence of depressed central sensitization.

How Ketalin is Used: Administration Guidelines

Ketalin (ketamine hydrochloride injection) is used as a general anesthetic agent associated with specific administration parameters that define its procedural application. These parameters establish the route, frequency, and dosage ranges for its use in acute medical settings.

---

Administration Scope

Feature	Guideline
Route of Administration	Administered as a sterile aqueous solution via Intravenous (IV) injection or continuous infusion, or via Intramuscular (IM) injection.
Dosing Schedule	Dosing is calculated by body weight on a mg/kg basis. The IV Induction Dose ranges from 1 mg/kg to 4.5 mg/kg. The IM Induction Dose ranges from 6.5 mg/kg to 13 mg/kg.
Preparation Requirements	The concentrated 100 mg/mL solution must be diluted before IV administration using standard solutions like 0.9% Sodium Chloride.
Age-Group Rules	Dose selection for older adults is typically cautious, starting at the lower end of the dosing range. Dose reductions are also considered for patients with hepatic impairment.

---

Procedural Structure

The administration sequence begins with determining the appropriate dose based on the patient's body weight. The IV dose is administered slowly over a minimum period of 60 seconds. Anesthesia is maintained by administering incremental doses, which are typically one-half to the full initial induction dose, as necessary. The medicine is suited for short procedures and is not indicated for long-term use. Furthermore, the use of this medicine occurs under the direct supervision of physicians experienced in general anesthetic techniques.

Research Evidence / Overview of Studies for Ketalin

---

Evidence for use in General Anesthesia and Procedural Sedation

The use of Ketalin's active ingredient has been studied for many decades in research exploring the induction of general anesthesia and procedural sedation, focusing on the speed of onset. The research base includes decades of Randomized Controlled Trials (RCTs) and extensive data from observational settings evaluating its application in clinical environments for various medical procedures. Studies monitored outcomes such as the time it takes to enter the anesthetic state and how systemic or functional imbalance metrics (like heart rate and blood pressure) evolved in the observed populations.

Research describes patterns observed in the studies, frequently monitoring the speed of onset of the dissociative anesthetic state. The substance was evaluated in populations, including adults and children undergoing various medical procedures. Findings indicate that studies monitored how key physiological metrics evolved during the anesthetic phase. Data for certain highly specialized surgical procedures and rarely encountered patient subgroups are limited.

Evidence for use in Acute and Chronic Pain Management

Ketalin's active ingredient was also studied for managing acute and chronic pain. For acute pain (such as after trauma or surgery), research describes patterns observed in these studies where physical discomfort outcomes were measured. Some trials exploring short-term symptom changes monitored measurements related to the requirement for concurrent pain medications in the immediate post-procedure setting.

However, when applied in studies examining patient-reported experiences related to chronic pain, findings were mixed across studies. A Cochrane review found that the evidence for benefit in chronic pain is rated as low to very low certainty, citing small study sizes and poor methodological quality. Consequently, comparative evidence between acute and chronic pain applications remains limited, and comprehensive data on long-term outcomes for chronic conditions are not fully established.

Evidence for use in Treatment-Resistant Depression

Ketalin’s active ingredient was evaluated in specific populations with Treatment-Resistant Depression (TRD). Research examined short-term symptom changes following single or repeated infusions. Studies monitored outcomes such as changes in standardized depression severity scores and scores reflecting acute suicidal risk. Research exploring short-term symptom changes reported the rapidity of change in symptom scores in the observed populations who were studied during periods of increased symptom activity.

Studies tracked the time course of symptom changes measured during the study period, which were often not sustained after a single dose. Consequently, certainty remains low regarding the durability of the response. Furthermore, data for repeated or long-term administration (e.g., beyond three months) are limited.

What is Still Uncertain about Ketalin Research

The body of research, while extensive in anesthesia, still contains several limitations when applied to the full spectrum of other indications. Evidence quality varies across studies, particularly for chronic pain, where many trials had modest sample sizes and different treatment protocols were used. Long-term effects are not fully established for the repeated use often required for chronic conditions, and evidence for sustained, long-term outcomes across certain non-anesthesia indications remains limited.

Common questions about Ketalin (FAQ)

Q: Is Ketalin a controlled substance, and what schedule is it?

Yes, the active ingredient in Ketalin (ketamine) is formally classified as a controlled substance by regulatory bodies. In the United States, for example, official documents list it as a Schedule III non-narcotic controlled substance. This classification requires that its storage, handling, and dispensing adhere to specific government regulations to manage the risk of misuse.

---

Q: What is the onset of action for Ketalin when administered intravenously?

According to official product information, when Ketalin is administered via intravenous (IV) injection, the onset of the anesthetic effect is very rapid. It typically achieves the necessary level of surgical anesthesia within approximately 30 seconds of being injected. This rapid action is a key characteristic described in the drug's product information.

---

Q: Can Ketalin cause permanent brain damage in children?

Regulatory documents include warnings concerning the use of Ketalin in very young children, specifically those under 3 years old. These warnings address the potential for neurotoxicity (harm to nerve cells) and long-term cognitive deficits based on evidence from animal studies, particularly with repeated or prolonged exposure. Regulatory documents advise cautious use in this population due to these potential risks.

---

Q: How quickly do the psychiatric side effects resolve after the drug wears off?

The psychiatric effects that may occur during recovery, sometimes called emergence reactions (such as confusion, vivid dreams, or hallucinations), are generally transient (short-lived). Official safety information indicates these effects usually last for a few hours. However, recurrence of symptoms has been noted in some cases for up to 24 hours after the medicine was administered.

---

Q: How is the 100 mg/mL solution physically prepared for IM injection?

For intramuscular (IM) injection, the concentrated 100 text mg/mL solution of Ketalin is typically administered without dilution. The regulatory instructions state that the requirement to dilute the concentrated solution only applies when the medicine is being prepared for intravenous (IV) administration.

How to Store and Dispose of Ketalin

Ketalin (ketamine injection) must be stored and handled according to official regulatory requirements, reflecting its status as a controlled substance and injectable solution.

Storage Requirements

The medicine should be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), and must be protected from light. It is mandatory that the product not freeze. As a controlled substance, it must be stored locked up and kept out of reach of children.

Handling and Stability

When diluted for intravenous use, the solution must be used immediately. Multi-dose vials should be discarded 28 days after initial entry. Do not mix Ketalin with barbiturates in the same container due to chemical incompatibility.

Disposal Instructions

Unused or expired Ketalin should be returned to an authorized drug take-back program. If a take-back program is unavailable, follow the official procedure for disposing of controlled substances in household trash. Disposal must not be conducted via wastewater.